Tweet
Comerica Bank lessened its stake in shares of AmerisourceBergen Corp. (NYSE:ABC) by 9.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 45,872 shares of the company's stock after selling 4,719 shares during the period. Comerica Bank's holdings in AmerisourceBergen were worth $3,982,000 at the end of the most recent reporting period.
A number of other institutional investors also recently bought and sold shares of ABC. First Mercantile Trust Co. bought a new position in AmerisourceBergen during the 2nd quarter worth $107,000. Bronfman E.L. Rothschild L.P. increased its stake in AmerisourceBergen by 54.8% during the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 1,698 shares of the company's stock worth $146,000 after acquiring an additional 601 shares during the period. Piedmont Investment Advisors LLC bought a new position in AmerisourceBergen during the 2nd quarter worth $157,000. K.J. Harrison & Partners Inc bought a new position in AmerisourceBergen during the 2nd quarter worth $200,000. Finally, Synovus Financial Corp bought a new position in AmerisourceBergen during the 1st quarter worth $202,000. Hedge funds and other institutional investors own 66.68% of the company's stock. Get AmerisourceBergen alerts:
Shares of ABC opened at $86.82 on Friday. AmerisourceBergen Corp. has a 52-week low of $71.90 and a 52-week high of $106.27. The company has a debt-to-equity ratio of 1.39, a quick ratio of 0.51 and a current ratio of 0.94. The firm has a market capitalization of $17.74 billion, a PE ratio of 14.47, a price-to-earnings-growth ratio of 1.28 and a beta of 1.00. AmerisourceBergen (NYSE:ABC) last issued its quarterly earnings results on Thursday, August 2nd. The company reported $1.54 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.46 by $0.08. AmerisourceBergen had a return on equity of 48.65% and a net margin of 0.69%. The company had revenue of $43.14 billion for the quarter, compared to analyst estimates of $43.05 billion. During the same quarter last year, the company posted $1.43 EPS. The company's revenue for the quarter was up 11.4% compared to the same quarter last year. equities research analysts expect that AmerisourceBergen Corp. will post 6.48 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 4th. Investors of record on Monday, August 20th will be issued a dividend of $0.38 per share. This represents a $1.52 annualized dividend and a dividend yield of 1.75%. The ex-dividend date of this dividend is Friday, August 17th. AmerisourceBergen's dividend payout ratio (DPR) is 25.85%.
In related news, insider Robert P. Mauch sold 1,000 shares of the firm's stock in a transaction on Wednesday, June 13th. The stock was sold at an average price of $90.00, for a total transaction of $90,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website . Also, CEO Steven H. Collis sold 21,350 shares of the firm's stock in a transaction on Friday, June 1st. The shares were sold at an average price of $83.08, for a total value of $1,773,758.00. Following the sale, the chief executive officer now directly owns 287,925 shares in the company, valued at approximately $23,920,809. The disclosure for this sale can be found here . In the last three months, insiders have sold 102,682 shares of company stock worth $8,546,719. 27.30% of the stock is currently owned by company insiders.
A number of equities analysts have commented on the company. ValuEngine upgraded AmerisourceBergen from a "sell" rating to a "hold" rating in a research note on Wednesday. Robert W. Baird restated a "neutral" rating and set a $94.00 price objective on shares of AmerisourceBergen in a research note on Friday, July 20th. Mizuho restated a "hold" rating and set a $90.00 price objective on shares of AmerisourceBergen in a research note on Sunday, August 12th. Finally, Morgan Stanley lowered their price objective on AmerisourceBergen from $97.00 to $88.00 and set an "equal weight" rating on the stock in a research note on Tuesday, July 3rd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company's stock. The company currently has a consensus rating of "Hold" and an average price target of $101.80.
AmerisourceBergen Company Profile
AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers.
Featured Story: Book Value Per Share â€“ BVPS
Want to see what other hedge funds are holding ABC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AmerisourceBergen Corp. (NYSE:ABC). Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with MarketBeat.com's FREE daily email newsletter 